Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIBF 1120 in Recurrent Small Cell Lung Cancer
NCT01441297Phase 2Completed
- Start
- Dec 2011
- Primary completion
- Oct 2015
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nintedanib in small cell lung cancer (SCLC). Primary endpoint: Overall Response Rate. Started Dec 2011; status: completed.
02
Drugs
nintedanib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT01441297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01441297.